Pharmacological study of bacterial lipopolysaccharide-induced airway hyperresponsiveness in guinea-pigs. 1991

H Nagai, and F Tsuji, and S Goto, and A Koda
Department of Pharmacology, Gifu Pharmaceutical University, Japan.

Bacterial lipopolysaccharide-induced airway hyperreactivity in guinea-pigs was investigated pharmacologically. Inhalation of bacterial lipopolysaccharide resulted in an increase in airway muscarinic reactivity, as measured by intravenous acetylcholine administration. Metopirone, an inhibitor of 11 beta-hydroxylase, increased the excretion of urinary 17-ketosteroid, displayed a tendency to lower plasma cortisone levels and increased lipopolysaccharide-induced bronchial hyperreactivity. After bacterial lipopolysaccharide was inhaled by metopirone-treated guinea-pigs, increased vascular permeability and an increased number of leukocytes in the pulmonary capillaries were observed. When prednisolone, alone or in combination with cyclophosphamide, was injected into the guinea-pigs, lipopolysaccharide-induced airway hyperreactivity was inhibited, along with the simultaneous disappearance of inflammatory signs in the airway. Tranilast and ketotifen, reported in clinical studies to inhibit airway hyperreactivity, inhibited hyperreactivity induced by lipopolysaccharide and increased vascular permeability in the pulmonary capillaries, without affecting the increase in leukocytes. These results indicate that increased permeability in pulmonary capillaries is an important factor in the induction of lipopolysaccharide-induced bronchial hyperreactivity in guinea-pigs, and that this model is useful for the pharmacological study of airway hyperreactivity.

UI MeSH Term Description Entries
D007665 Ketotifen A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one,Ketotifen Fumarate,Ketotifene,Ketotiphen,Ketotiphene,Zaditen,Fumarate, Ketotifen
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008797 Metyrapone An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME. Methbipyranone,Methopyrapone,Metopiron,Metopirone,Métopirone,SU 4885
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002199 Capillary Permeability The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement. Microvascular Permeability,Permeability, Capillary,Permeability, Microvascular,Vascular Permeability,Capillary Permeabilities,Microvascular Permeabilities,Permeabilities, Capillary,Permeabilities, Microvascular,Permeabilities, Vascular,Permeability, Vascular,Vascular Permeabilities
D003348 Cortisone A naturally occurring glucocorticoid that has been used in replacement therapy for ADRENAL INSUFFICIENCY and as an anti-inflammatory agent. Cortisone itself is inactive; it is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726) 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate,Adreson,Cortisone Acetate,Cortone Acetate
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

H Nagai, and F Tsuji, and S Goto, and A Koda
December 1996, Prostaglandins,
H Nagai, and F Tsuji, and S Goto, and A Koda
November 1989, Arerugi = [Allergy],
H Nagai, and F Tsuji, and S Goto, and A Koda
August 1998, Arerugi = [Allergy],
H Nagai, and F Tsuji, and S Goto, and A Koda
June 2002, Research report (Health Effects Institute),
H Nagai, and F Tsuji, and S Goto, and A Koda
May 2000, American journal of respiratory and critical care medicine,
H Nagai, and F Tsuji, and S Goto, and A Koda
May 1998, American journal of respiratory and critical care medicine,
H Nagai, and F Tsuji, and S Goto, and A Koda
April 1997, Biological & pharmaceutical bulletin,
H Nagai, and F Tsuji, and S Goto, and A Koda
July 2003, Biological & pharmaceutical bulletin,
H Nagai, and F Tsuji, and S Goto, and A Koda
April 1989, Arerugi = [Allergy],
H Nagai, and F Tsuji, and S Goto, and A Koda
June 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Copied contents to your clipboard!